Outlook Therapeutics OTLKW 深 沪

Outlook Therapeutics stock slides after pricing $5M offering

Outlook Therapeutics (OTLK) shares fell 34% in premarket trading Tuesday after the company priced a public offering. The biopharma firm is selling 20M shares along with warrants to buy up to 20M share...

03-24 19:11

Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket

PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.

03-24 17:31

Outlook Therapeutics launches public offering; shares down

Outlook Therapeutics (OTLK) has initiated a best-efforts public offering of common stock and accompanying warrants. The offering may include pre-funded warrants in place of common stock. The offering ...

03-24 05:41

Outlook Therapeutics Reveals Proposed Public Offering; No Size Disclosed

Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts

03-24 05:35

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics, Inc. announced the launch of a public offering of its common stock and warrants, with proceeds intended for working capital and general corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent. The offering is under a shelf registration statement, and a prospectus supplement will be filed with the SEC. The company, focused on enhancing care for retina diseases, aims to commercialize its ophthalmic be...

03-23 21:30

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

03-16 12:05

Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.

03-11 20:19

Outlook Therapeutics Shareholders Back Board, Pay, and Auditor

The latest update is out from Outlook Therapeutics ( ($OTLK) ). At its annual m...

03-11 10:35

Outlook Therapeutics Evaluating Available Regulatory Options To Move Ahead ONS-5010/LYTENAVA Toward Potential U.S. Approval After FDA Meeting

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A

03-06 05:26

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics provided an update after a Type A meeting with the FDA to address the Complete Response Letter for its BLA of ONS-5010/LYTENAVA™. The meeting aimed to clarify issues regarding confirmatory evidence of effectiveness and discuss potential approval pathways. The company remains committed to working with the FDA and evaluating regulatory options. ONS-5010 has shown significant clinical benefits in trials for wet AMD and has a fav...

03-05 21:15